Table 3.
Haplogroup distribution of North African Jewish (NAF) T2DM patients who developed complications and the "No complications" group as in table 1. Patients included in this table may have more than one complication.
| Haplogroup | All NAF n (%) | No complication n (%) | Cardiovascular n (%) | Retino-pathy n (%) | Nephro-pathy n (%) |
| U (nonK) | 21 (9.4) | 9 (12.3) | 5 (9.8) | 3 (5) | 8 (9.1) |
| K | 32 (14.3) | 12 (16.4) | 4 (7.8) | 10 (16.7) | 9 (10.2) |
| 1HV* | 35 (15.7) | 6 (8.2) | 13 (25.4) | 12 (20) | 19 (21.6) |
| H | 72 (32.3) | 20 (27.4) | 20 (39.2) | 22 (36.7) | 30 (34.1) |
| J1** | 8 (3.6) | 5 (6.8) | 1 (2) | 0 | 3 (3.4) |
| T | 7 (3.1) | 4 (5.5) | 1 (2) | 1 (1.7) | 2 (2.3) |
| WXI | 23(10.3) | 9 (12.3) | 4 (7.8) | 4 (6.7) | 8 (9.1) |
| 2Others | 25 (11.2) | 8 (11) | 3 (5.9) | 8 (13.3) | 9 (10.2) |
| Total | 223 | 73 | 51 | 60 | 88 |
1HV* – see table 1.2Others – see table 1. **After removing the J2 patients (see Materials and Methods), we were left only with J1 patients; thus, the sample size was reduced from 226 to 223 for the total population and the complications groups were adjusted accordingly.